Naftopidil-d7

• Description:

  Naftopidil-d7 (KT-611-d7) is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

• Product Name Alternative:

  KT-611-d7 ; BM-15275-d7

• UNSPSC:

  12352005

• Target:

  Adrenergic Receptor; Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling; Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cardiovascular Disease; Endocrinology

• Smiles:

  OC (CN1CCN (CC1) C2=C (OC) C=CC=C2) COC3=C ([2H]) C ([2H]) =C ([2H]) C4=C3C ([2H]) =C ([2H]) C ([2H]) =C4[2H]

• Molecular Formula:

  C24H21D7N2O3

• Molecular Weight:

  399.53

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]R Takei, et al. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol. 1999 Apr;79 (4) :447-54.|[3]Yasuhide Hori, et al. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila) . 2011 Jan;4 (1) :87-96.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported